Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Margaret A Tempero

Showing results (1-10 of 65) with videos related to

Pageof 7
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|May 22, 2015
Multidisciplinary management of pancreatic cancerMargaret A Tempero
Journal of the National Comprehensive Cancer Network : JNCCN|May 23, 2019
NCCN Guidelines Updates: Pancreatic CancerMargaret A Tempero
Cancer Journal (Sudbury, Mass.)|November 29, 2012
Monoclonal antibodies and other targeted therapies for pancreatic cancerPelin Cinar, Margaret A Tempero
Seminars in Radiation Oncology|September 27, 2005
Systemic therapy for pancreatic cancerAndrew H Ko, Margaret A Tempero
Journal of the National Comprehensive Cancer Network : JNCCN|October 1, 2005
Treatment of metastatic pancreatic cancerAndrew H Ko, Margaret A Tempero
Current Oncology Reports|April 9, 2002
Current and future strategies for combined-modality therapy in pancreatic cancerAndrew H Ko, Margaret A Tempero
Gastroenterology|April 30, 2013
Therapeutic advances in pancreatic cancerAndrew Scott Paulson, Hop S Tran Cao, Margaret A Tempero, et al.
American Journal of Clinical Oncology|October 22, 2019
CA 19-9 Response: A Surrogate to Predict Survival in Patients With Metastatic Pancreatic AdenocarcinomaCelso L Diaz, Pelin Cinar, Jimmy Hwang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2005
Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreasAndrew H Ko, Elizabeth Dito, Brian Schillinger, et al.
Cancer Investigation|January 9, 2008
Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II studyAndrew H Ko, Elizabeth Dito, Brian Schillinger, et al.
Pageof 7

Showing results (1-10 of 65) with videos related to

Sort By:
Pageof 7
Journal of the National Comprehensive Cancer Network : JNCCN|May 22, 2015
Multidisciplinary management of pancreatic cancerMargaret A Tempero
Journal of the National Comprehensive Cancer Network : JNCCN|May 23, 2019
NCCN Guidelines Updates: Pancreatic CancerMargaret A Tempero
Cancer Journal (Sudbury, Mass.)|November 29, 2012
Monoclonal antibodies and other targeted therapies for pancreatic cancerPelin Cinar, Margaret A Tempero
Seminars in Radiation Oncology|September 27, 2005
Systemic therapy for pancreatic cancerAndrew H Ko, Margaret A Tempero
Journal of the National Comprehensive Cancer Network : JNCCN|October 1, 2005
Treatment of metastatic pancreatic cancerAndrew H Ko, Margaret A Tempero
Current Oncology Reports|April 9, 2002
Current and future strategies for combined-modality therapy in pancreatic cancerAndrew H Ko, Margaret A Tempero
Gastroenterology|April 30, 2013
Therapeutic advances in pancreatic cancerAndrew Scott Paulson, Hop S Tran Cao, Margaret A Tempero, et al.
American Journal of Clinical Oncology|October 22, 2019
CA 19-9 Response: A Surrogate to Predict Survival in Patients With Metastatic Pancreatic AdenocarcinomaCelso L Diaz, Pelin Cinar, Jimmy Hwang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2005
Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreasAndrew H Ko, Elizabeth Dito, Brian Schillinger, et al.
Cancer Investigation|January 9, 2008
Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II studyAndrew H Ko, Elizabeth Dito, Brian Schillinger, et al.
Pageof 7